TWEAKR was highly expressed in glioma and esophageal adenocarcinoma cell lines and cooperated with invasive activity; in addition, it is a potential cell surface portal for the targeted delivery of glioblastoma therapeutics. The gene discussed is TNFRSF12A; the disease is glioma.